Biotech Values

[DewDiligence]

I don't think MNTA ever used up their TLCF (tax loss carry forwards). And they are again losing money.

Two points:

1. MNTA did exhaust all—or almost all—of its tax-loss carryforwards.

2. The value of the Lovenox royalty stream to another company that pays taxes must be computed on an after-tax basis; hence, the after-tax value is what dictates how much MNTA could expect to obtain by monetizing this asset.